PICALM阿尔茨海默氏症风险基因导致微质中异常的脂质滴
Alena Kozlova1,2, Siwei Zhang1,2, Ari Sudwarts3,4
1Center for Psychiatric Genetics, Endeavor Health Research Institute, Evanston, IL, USA.
Nature
|September 3, 2025
概括
在微质中与阿尔茨海默氏症风险相关的遗传变异通过增加脂质滴积累来损害其功能. 这一发现揭示了阿尔茨海默病 (AD) 免疫细胞易受伤害的新机制.
科学领域:
- 神经科学
- 遗传学
- 免疫学
背景情况:
- 全基因组关联研究 (GWAS) 已经确定了许多晚期阿尔茨海默病 (LOAD) 的遗传风险位点.
- 然而,导致LOAD的确切疾病机制和因果变异在很大程度上尚不清楚.
- 识别功能变异及其细胞表型对于理解LOAD病原体至关重要.
研究的目的:
- 确定与LOAD风险相关的功能遗传变异.
- 确定与这些风险变体相关的细胞表型,特别是脑免疫细胞 (微细胞).
- 阐明PICALM基因在微质内LOAD病变的作用.
主要方法:
- 在人类诱导多能干细胞 (iPSC) 衍生的神经元,星球细胞和微质细胞中利用基因特异性开放色素映射.
- 研究了特定的LOAD风险等位基因 (rs10792832) 在PICALM位点的功能影响.
- 进行了微质的遗传和药理学乱,以评估PICALM在脂质代谢和细胞的作用.
主要成果:
- 已确定26个LOAD风险位的功能风险变异,主要在微质中.
- 证明PICALM位点的LOAD风险等位基因损害了转录因子结合 (PU.1) 并降低了微质中的PICALM表达.
- 显示PICALM表达减少导致粉样β和髓碎片的吸收受损,增加胆固醇合成,并在微质中积累脂质滴.
结论:
- 通过有害的脂质滴积累驱动的PICALM位点的LOAD脆弱性的微细胞特异机制.
- 建立了减少PICALM表达,脂质滴积和微细胞缺陷之间的因果关系.
- 提供了PICALM在LOAD中的作用的神经生物学基础,为治疗干预提供了潜在的目标.
相关概念视频
Alzheimer's Disease: Overview
666
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
666
Amyloid Fibrils
9.8K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.8K


